Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Preliminary Meetings of Regulatory Consultations Reach 331, Increase Found in Central and Peripheral Nervous System Drugs
January 25, 2013
- New Government Economic Panel Holds First Meeting, Takeda President Hasegawa Proposes to Bring Competition to Medical Industry
January 25, 2013
- Premium for New Drug Development to Be Discussed Alongside Long-Listed Drugs, Development of Drugs Used Off-Label: Health Minister Tamura
January 25, 2013
- Draft Basic Policy for FY2013 Budget Calls for “Prioritization” in Social Security to Minimize Increase in Public Burden
January 24, 2013
- MHLW Proposes Adding Test for Alcohol Consumption and Dependence to Health Checkup Program
January 24, 2013
- MOF’s Fiscal System Council Continues to Back Reference Price System, Price Cuts for Long-Listed Drugs
January 23, 2013
- LDP Group to Make New Rules on Online OTC Drug Sales in the Diet Session, Consider Lawmaker-Sponsored Bill
January 22, 2013
- PAFSC’s 2nd Committee to Discuss GSK’s CLL Treatment Arzerra on January 31
January 21, 2013
- MHLW Mulling Measure to Encourage Welfare Recipients to Use Generics
January 21, 2013
- How Will Party’s Return Affect Healthcare and Drug Policy? LDP Back in Power for First Time in 3 Years
January 17, 2013
- MHLW to Launch Panel by Jan.-End to Discuss New Rule for Online OTC Drug Sales after Top Court Ruling
January 16, 2013
- MHLW to Make HPV, Hib, and Pneumococcal Vaccines Mandatory, Excluding Them from the FY2012 Extra Budget
January 16, 2013
- At Request of JMA, Pharmacists to Be Required to Confirm that Buyers of Switch OTC Version of Epadel Had Medical Exam Before Purchase
January 15, 2013
- Supreme Court OKs Online Sales of OTC Drugs, Rejects Govt Appeal
January 15, 2013
- MHLW Calls for Preventive Measures against Accidental Ingestion of Pharmaceutical Products by Children
January 15, 2013
- Focus May Be on Whether New Price Cutting Rule for Long-Listed Drugs Should Apply Only to Those Granted Premium
January 15, 2013
- MHLW Revises GCP Ordinance, Pushes Clinical Trials with Simple Contract Procedures
January 11, 2013
- PMDA Probes How Insurance Pharmacies Utilize Drug Safety Information
January 11, 2013
- MHLW’s Revised Budget Request for FY2013 under LDP for Innovation-Related Spending 40% Less than under DPJ
January 11, 2013
- MHLW Approves 2 Switch OTC Versions of Epadel
January 7, 2013
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…